The primary objective of the Biomedical Informatics Core (BMIC) is to facilitate the collecfion, management, ntegration, and analysis of a complete spectrum of information types required for the efficient operation of the SPORE'S projects, pilots, and other cores. Examples of these informafion types include stmctured and semi-structured data sets resulting from: 1) experimental studies;2) biostatistical analyses;3) fissue core and administrative operations;4) shared resource services;and 5) the asynchronous collaborafion of SPORE participants. We will achieve this objecfive using a combinafion biomedical informafics best practices and advanced technologies already in use or under development within The Ohio State University (OSU) Department of Biomedical Informafics (OSU-BMI) and The Ohio State University Comprehensive Cancer Center (OSU-CCC). Such technologies include: 1) the service-oriented caGrid middleware for electronic data interchange between heterogeneous biomedical data sources and analytical services;2) advanced database management systems optimized for the storage and query of rapidly evolving biomedical data sets;3) centralized ontology services and ontology-anchored knowledge discovery/management tools; 4) mulfiple task-specific web-portal applicafions that support the discovery, integration, and analysis of large scale, multi-dimensional data sets;and 5) web-based collaborative team-science tools. We envision the BMIC as being the central information coordination """"""""hub"""""""" of the SPORE. In order to achieve these objectives, the specific aims of the biomedical informafics core are to: 1) develop and support extensible database management systems for use by SPORE participants;2) enable electronic data interchange between SPORE-related data sources;3) support task-specific web portal applications that allow end users to discover, integrate, and analyze SPORE-related data sources;4) support the execution of SPORE-related clinical trials through the facilitation of access to the OSU-CCC's enterprise-grade clinical trials management system;and 5) implement and support a collaborative web portal intended to serve as a medium for both team-science and public disseminafion acfivities.

Public Health Relevance

The Biomedical Informafics Core's (BMIC) activifies as part of this SPORE will cover a wide spectrum, from the facilitafion of high-throughput data analyses to the provision of tools to enable the collaboration of temporally or geographically distributed investigators. As such, the BMIC will serve as a catalyst for the rapid and efficient conduct of translational studies, with the effect of accelerating the translafion and dissemination of basic science discoveries into clinical practice and ultimately public health benefits.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140158-04
Application #
8380671
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
4
Fiscal Year
2012
Total Cost
$130,864
Indirect Cost
$63,889
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Walker, C J; Eisfeld, A-K; Genutis, L K et al. (2017) No evidence for microsatellite instability in acute myeloid leukemia. Leukemia 31:1474-1476
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2017) Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Res 77:207-218
Park, I-K; Blum, W; Baker, S D et al. (2017) E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia. Leukemia 31:502-505
Papaioannou, Dimitrios; Shen, Changxian; Nicolet, Deedra et al. (2017) Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci U S A 114:E4641-E4647
Eisfeld, A-K; Kohlschmidt, J; Schwind, S et al. (2017) Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 31:1278-1285
Papaioannou, Dimitrios; Nicolet, Deedra; Volinia, Stefano et al. (2017) Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica 102:1391-1400
Wiczer, Tracy E; Levine, Lauren B; Brumbaugh, Jessica et al. (2017) Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv 1:1739-1748
Miller, Cecelia R; Ruppert, Amy S; Heerema, Nyla A et al. (2017) Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv 1:1584-1588
Mani, R; Yan, R; Mo, X et al. (2017) Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma. Vet Comp Oncol 15:1115-1118

Showing the most recent 10 out of 223 publications